Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease.
Alzheimer's disease and glaucoma: imaging the biomarkers of neurodegenerative disease.
复制标题
DOI：
10.4061/2010/793931
复制
发表时间：
2011-01-05
影响因子：
--
通讯作者：
Valenti DA
中科院分区：
文献类型：
--
作者：
Valenti DA
通过视觉系统对阿尔茨海默氏病进行成像，该技术目前广泛用于诊断和治疗青光眼和黄斑变性等眼部疾病，被证明是有前途的。十年来，年度综合眼部检查期间的体内横截面成像可用于治疗青光眼和黄斑变性，并且使用光学相干断层扫描的相同成像已被证明可以显示 AD 和轻度认知障碍特有的缺陷。这些缺陷表现为视网膜和视神经中神经纤维层组织脱落。视网膜和视神经中神经纤维层组织的逆行性丧失可能是 AD 的早期生物标志物，而视网膜和视神经神经纤维层的这些缺陷可能是 AD 的最早迹象，甚至早于影响记忆的海马区损伤。
Imaging through the visual system in Alzheimer's disease, with the technology currently in widespread use for the diagnosis and management of eye disease such as glaucoma and macular degeneration, is proving to be promising. In vivo cross-section imaging during an annual comprehensive eye exam has been available for a decade for glaucoma and macular degeneration, and this same imaging, using Optical Coherence Tomography, has been demonstrated to show deficits specific to AD and mild cognitive impairment. These deficits are in the form of nerve fiber layer tissue drop out in the retina and optic nerve. The retrograde loss of nerve fiber layer tissue in the retina and optic nerve may be an early biomarker of AD, and these deficits in the nerve fiber layer of the retina and optic nerve may be the earliest sign of AD, even prior to damage to the hippocampal region that impacts memory.